Study of neurotrophic factor receptor tyrosine kinase gene fusion in the precise treatment of wild-type gastrointestinal stromal tumor.
10.3760/cma.j.cn.441530-20210831-00349
- VernacularTitle:神经营养因子受体酪氨酸激酶基因融合在野生型胃肠间质瘤精准诊治中的研究
- Author:
Hai Dong ZHANG
1
;
Xiao Nan YIN
1
;
Zhao Lun CAI
1
;
Bo ZHANG
2
Author Information
1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
2. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China Department of Gastrointestinal Surgery, Sanya People's Hospital, West China Sanya Hospital, Sichuan University, Hainan Sanya 572000, China.
- Publication Type:Journal Article
- Keywords:
Gastrointestinal stromal tumor, wild-type;
Neurotrophic factor receptor tyrosine kinase (NTRK) gene;
Precise therapy;
Tyrosine kinase inhibitors
- MeSH:
Gastrointestinal Stromal Tumors/genetics*;
Gene Fusion;
Humans;
Neoplasms;
Nerve Growth Factors;
Protein Kinase Inhibitors;
Receptor, trkA/genetics*;
Receptors, Nerve Growth Factor/genetics*
- From:
Chinese Journal of Gastrointestinal Surgery
2021;24(9):769-774
- CountryChina
- Language:Chinese
-
Abstract:
The neurotrophin receptor kinase (NTRK) gene encodes neurotrophic factor receptor tyrosine kinase (NTRK), which plays an important role in the development and function of the nervous system. NTRK gene fusion mutation results in the production of chimeric NTRK proteins, which have carcinogenic potential through constitutive activation or overexpression. NTRK gene fusion mutation can lead to a special type of wild type gastrointestinal stromal tumor (GIST), whose clinical manifestations and treatment are completely different from other types of GIST. This fusion mutation can be detected clinically by a variety of methods, including tumor DNA and RNA sequencing and immunohistochemical staining. In patients with NTRK fusion positive tumors, NTRK inhibitors such as larotrectinib and entrectinib have shown good antitumor efficacy, with clinical response rates as high as 75%. Therefore, there is a need to improve the recognition and detection of fuch patients and to improve their prognosis by individualized and precise treatment with TRK inhibitors.
